Proclara Biosciences, Inc.

Amyl Therapeutics Srl

Robert G E Holgate

Francis Joseph Carr

Timothy David Jones

Richard Fisher

Rajaraman Krishnan

Eva Asp

Ming Proschitsky

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal

Growing community of inventors

Royston, United Kingdom

Robert G E Holgate